Pfizer Inc., of New York, said the European Commission gave conditional marketing authorization for Xalkori (crizotinib) for the treatment of adults with previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

Pfizer Inc., of New York, said it is buying NextWave Pharmaceuticals Inc., of Cupertino, Calif., a privately held specialty pharmaceutical company focused on the treatment of attention deficit/hyperactivity disorder (ADHD) and related central nervous system disorders

Pfizer Inc., of New York, said the European Commission granted marketing authorization for Inlyta (axitinib) in adult patients with advanced renal cell carcinoma after failure of prior treatment with Sutent (sunitinib) or a cytokine

Pfizer Inc., of New York, reported top-line data assessing the immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age

In other news, BioLineRx said results from the Phase II EAGLE trial of BL-1020, an oral GABA-enhanced antipsychotic, published in the Journal of Clinical Psychiatry, showed that the drug was safe and effective in improving schizophrenia, in addition to improving cognitive impairment associated with the disease...In other news, Evotec and Aspireo Pharmaceuticals Ltd., of Tel Aviv, Israel, said they inked an advisory agreement for support in the development and partnering of Aspireo's Somatoprim

Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, said the FDA accepted the new drug application resubmission for Eliquis (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation

The plant cell-based drug gained approval earlier this year in the U.S., where it is marketed by partner Pfizer Inc., of New York, but the European Committee for Medicinal Products for Human Use recommended against approval, citing the 10-year exclusivity for Dublin, Ireland-based Shire plc's Gaucher drug Vpriv (velaglucerase alfa). (See BioWorld Today, May 3, 2012, and June 25, 2012

In other news, BMS and partner Pfizer Inc., of New York, said the European Committee for Medicinal Products for Human Use adopted a positive opinion on Eliquis (apixaban) for the prevention of stroke and systemic embolism in adults with nonvalvular atrial fibrillation and one or more risk factors for stroke

Open Monoclonal Technology Inc., of Palo Alto, Calif., inked a deal allowing Pfizer Inc., of New York, rights to use its OmniRat platform for antibody research and development

Pfizer Inc., of New York, said the World Health Organization granted an expansion to the prequalification of Pfizer's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), to include adults 50 and older against pneumonia and invasive disease caused by the 13 pneumococcal serotypes in the vaccine

Pfizer Inc., of New York, said it settled litigation against Mylan Inc., of Pittsburgh, and Mylan Pharmaceuticals Inc

SFJ Pharmaceuticals Group, of San Francisco, entered a collaborative development agreement with Pfizer Inc., of New York, to conduct a Phase III trial of Pfizer's investigational pan-human epidermal growth factor receptor inhibitor dacomitinib (PF-00299804

Pfizer Inc., of New York, said the FDA approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML

VLST Corp., of Seattle, said it signed an in-licensing agreement with New York-based Pfizer Inc

Theraclone Sciences Inc., of Seattle, said New York-based Pfizer Inc

Pfizer Inc., of New York, and Mylan Inc., of Pittsburgh, said they signed a definitive agreement to establish an exclusive long-term strategic collaboration to develop, manufacture, distribute and market generic drugs in Japan

Pfizer Inc., of New York, reported that the FDA extended the action date for its new drug application for tofacitinib, an investigational oral treatment for adults with moderately to severely active rheumatoid arthritis (RA), by three months

Pfizer Inc., of New York, licensed the exclusive rights to Pittsburg-based Mylan Inc.'s next-generation EpiPen Injection 0.3/0.15 mg in Japan

Pfizer Inc., of New York, will pay more than $60 million to resolve Department of Justice (DOJ) and SEC investigations into improper payments made by two of its subsidiaries outside the U.S. Pfizer H.C.P. Corp